Endpoints
The primary endpoint of this study was to assess the protective effect
of benralizumab and mepolizumab against the AHR elicited by histamine in
hyperresponsive human bronchi.
The secondary endpoints included the impact of benralizumab and
mepolizumab against the AHR elicited by EFS and mechanical stress
induced by quick stretch (QS), and the effect of these mAbs on the
modulation of cAMP levels in hyperrespnsive bronchial tissue.